Clinical Study
Changes in Osteoblastic Activity in Patient Who Received Bortezomib as Second Line Treatment for Plasma Cell Myeloma: A Prospective Multicenter Study
Table 2
Changes in bone markers.
| Variables | Pretreatment | Posttreatment | Difference† | |
| (%) | 75 (100.0) | 73 (97.3) | 73 (97.3) | | Osteocalcin ECLIA (ng/mL) | 17.7 ± 18.6 | 13.7 ± 16.0 | 4.0 ± 15.9 | <0.0001 | Bone ALP (U/L) | 25.9 ± 16.2 | 21.8 ± 11.2 | 4.2 ± 14.3 | 0.004 | DKK-1 (pmol/L) | 136.4 ± 86.3 | 116.3 ± 58.8 | 20.2 ± 78.6 | 0.035 | sRANKL (total, pmol/L) | 75.1 ± 86.8 | 48.4 ± 47.2 | 28.1 ± 101.6 | 0.011 | OPG (pmol/L) | 3.9 ± 1.8 | 4.0 ± 1.9 | −0.1 ± 1.1 | 0.464 | sRANKL/OPG ratio | 22.2 ± 34.4 | 13.5 ± 16.1 | 9.4 ± 36.6 | 0.037 |
|
|
ECLIA: electrochemiluminescence immunoassay. †Pretreatment value − posttreatment value.
|